이달의 증례
| Thalidomide and a Dipeptidyl Peptidase 4 Inhibitor in a Rat Model of Experimental Autoimmune Myocarditis | |||
|---|---|---|---|
| 년도 | 2023년 12월 | ||
| 카테고리 | 이달의 kcj Hot Article | ||
| 저자 | Kyung-Jin Kim, MD, PhD,1 Jun-Bean Park, MD, PhD,2 Seung-Pyo Lee, MD, PhD,3 Hyung-Kwan Kim, MD, PhD,2 and Yong-Jin Kim, MD, PhD2 | ||
| 소속 | 1Department of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul, Korea. 2Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. |
||
| 첨부파일 1 | kcj-53-795-abf001.jpg | ||
- 관리자
- 등록일 : 2024.01.02
- Hit 91
Background and Objectives
Myocarditis is a potentially fatal disease, but curative treatments have not yet been established. Myocardial inflammation is an important pathogenesis of this disease, and immunosuppressants such as methylprednisolone and immunoglobulin have been used for treatment; however, the effectiveness needs to be improved. Thalidomide and dipeptidyl peptidase (DPP) 4 inhibitors were recently investigated regarding their immunomodulatory properties. This study aimed to test whether thalidomide or a DPP4 inhibitor (evogliptin) can improve the effectiveness of myocarditis treatment using a rat model of experimental autoimmune myocarditis (EAM).
Methods
Rats with or without myocarditis were administered thalidomide at 100 mg/kg/day and DPP4 inhibitor at 10 mg/kg/day orally. Measurement of echocardiography, serum inflammatory cytokines, myocardial histopathological examination, and immunohistochemical staining for leukocytes, macrophages, CD4+ T cells, and cytoskeleton were performed after 3 weeks, and the fibrosis area was measured after 3 and 6 weeks.
Results
Thalidomide and DPP4 inhibitor did not reduce the severity of myocarditis compared with the EAM without treatment rats by comparing the echocardiographic data, myocardial CD4+, macrophages, neutrophil infiltrations, and the heart weight/body weight ratio in 3 weeks. The levels of inflammatory cytokines were not lower in the thalidomide and DPP4 inhibitor-treated group than in the untreated group in 3 weeks. In 6 weeks, thalidomide and DPP4 inhibitors did not reduce the fibrosis area compared to untreated groups.
Conclusions
Although thalidomide and the DPP4 inhibitor had an immunomodulatory effect and are used against inflammatory diseases, they did not ameliorate myocardial inflammation and fibrosis in this rat model of EAM.
바로가기 : https://e-kcj.org/DOIx.php?id=10.4070/kcj.2023.0042
댓글 0
댓글 쓰기
[댓글 목록]
- 학회소개
- 학술 행사
- 학회지(KCJ)
- 심장학
최신지견 따라잡기
- 진료지침
- 자료실
- 회원공간
- 공지사항